Hyundai Pharmaceutical (004310) Fundamentals 2026 — P/E 40.0x, Revenue Analysis | SniperIQ
Hyundai Pharmaceutical (004310) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩152.7B, trading at ₩6510.00 on the KSC. This SniperIQ fundamentals page covers Hyundai Pharmaceutical's valuation (P/E 40.0x, P/B 1.6x), profitability (net margin 2.2%), revenue (₩191.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hyundai Pharmaceutical's market cap?
Hyundai Pharmaceutical (004310) has a market capitalization of approximately ₩152.7B, trading at ₩6510.00 on the KSC. Market cap moves with the live share price.
What is Hyundai Pharmaceutical's P/E ratio?
Hyundai Pharmaceutical's trailing twelve-month P/E ratio is 40.0x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hyundai Pharmaceutical?
Hyundai Pharmaceutical runs a net profit margin of 2.2%, a gross margin of 35.8%, and an operating margin of 3.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hyundai Pharmaceutical generate?
Hyundai Pharmaceutical reported revenue of ₩191.8B for fiscal year 2025, with net income of ₩2.5B and earnings per share (EPS) of 96.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hyundai Pharmaceutical pay a dividend?
Hyundai Pharmaceutical offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hyundai Pharmaceutical financially healthy?
Hyundai Pharmaceutical carries a debt-to-equity ratio of 0.39x and a current ratio of 1.69x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hyundai Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hyundai Pharmaceutical (004310) the key facts are: market cap ₩152.7B, P/E 40.0x, revenue ₩191.8B, 52-week range 3500-15960. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hyundai Pharmaceutical's full fundamentals live
Get Hyundai Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.